in this issue
Regions :: Western Europe :: Denmark
Lonza Signs Development and Manufacturing Agreement with Genmab
12:12 AM MDT | October 25, 2011 | Deepti Ramesh
Lonza says it has signed a development and manufacturing agreement with biotechnology company Genmab (Copenhagen, Denmark) for a novel antibody drug conjugate (ADC), HuMax-TF. This agreement secures a development and cGMP manufacturing plan for Genmab to produce a novel ADC product targeting tissue factor (TF), a protein involved in tumor signalling and angiogenesis that is highly expressed on solid tumors, Lonza says. Lonza will initiate process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF at its Slough, U.K. facility. The...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee